title: [The effects of nucleoside analogues on hepatitis B virus in hepatic lymph nodes of hepatitis B virus-associated liver transplantation recipients].
abstract: OBJECTIVE
  To investigate the effects of nucleoside analogues on hepatitis B virus (HBV) in hepatic lymph nodes of hepatitis B related liver transplantation recipients who were hepatitis B surface antigen (HBsAg) positive but negative for serum HBV DNA.
  
  
  METHODS
  From June 2010 to March 2011, thirty-six cases of hepatitis B related liver transplantation recipients [32 males, 4 females, average age (54 ± 7) years] were divided into drug treatment group and non-drug treatment group according to the utility of nucleoside analogues. Drug treatment group was divided into two subgroups: drug treatment > 3 months group and drug treatment ≤ 3 months group. The hepatic lymph nodes in the hepatoduodenal ligament were taken during the operation of liver transplant. Using nested or semi-nested PCR, HBV DNA and the replicative form HBV cccDNA in hepatic lymph nodes were detected. Data were analyzed by Fisher's exact test.
  
  
  RESULTS
  The positive rate of HBV DNA: the difference was not statistically significant between drug treatment group (72.7%, 16/22) and non-drug treatment group (14/14) (P = 0.062), the difference was not statistically significant between drug treatment > 3 months group (10/14) and drug treatment ≤ 3 months group (6/8) in the subgroups of drug treatment group (P = 1.000). The positive rate of HBV cccDNA: drug treatment group (22.7%, 5/22) was significantly lower than the non-drug treatment (12/14) (P = 0.000), drug treatment > 3 months group (1/14) was significantly lower than drug treatment ≤ 3 months group (4/8) in the subgroups of drug treatment group (P = 0.039).
  
  
  CONCLUSIONS
  Hepatic lymph nodes maybe one of the extrahepatic HBV reservoirs. Treating with nucleoside analogues more than 3 months can significantly decrease the replication of HBV in hepatic lymph nodes of HBV associated liver transplantation recipients.
authors.affiliation: Department of Transplant, Tianjin Medical University, Tianjin, China.
authors.forename: Ze
authors.initials: Z
authors.lastname: Chen
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
authors.forename: Rui
authors.initials: R
authors.lastname: Shi
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Zheng
authors.forename: Zhi-qiang
authors.initials: ZQ
authors.lastname: Chu
authors.forename: Hong-li
authors.initials: HL
authors.lastname: Song
authors.forename: Zhong-yang
authors.initials: ZY
authors.lastname: Shen
mesh_terms: D000328:Adult; D000368:Aged; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016031:Liver Transplantation; D008198:Lymph Nodes / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000627:therapeutic use*; D011300:Preoperative Care; D014779:Virus Replication
chemical_list: D004279:DNA, Viral; D009705:Nucleosides